BioNTech, the German drug company famous for developing a Covid-19 vaccine with Pfizer, has acquired AexeRNA and its novel lipid nanoparticles for mRNA medicines, Endpoints News has learned. AexeRNA is a tiny startup that largely exists on paper. It has no lab or staff scientists, just a former patent lawyer as its CEO and several scientific co-founders, including mRNA pioneer and recent Nobel Prize laureate Drew Weissman from the University of Pennsylvania, and bioengineer Michael Buschmann of George Mason University.
Read the full article: BioNTech Acquires Lipid Nanoparticle Startup Founded by George Mason and UPenn Scientists //
Source: https://endpts.com/biontech-acquires-lipid-nanoparticle-startup-founded-by-george-mason-and-upenn-scientists